Immunotherapies News and Research RSS Feed - Immunotherapies News and Research

MD Anderson researchers find way to predict patients who may respond to BRAF inhibitors

MD Anderson researchers find way to predict patients who may respond to BRAF inhibitors

Powerful drugs known as BRAF-inhibitors have been crucial for melanoma patients, saving lives through their ability to turn off the BRAF protein's power to spur cancer cell growth. [More]
Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. [More]
Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Cancer vaccines are designed to turn the body's own immune system specifically against tumor cells. Particularly promising are vaccines that are directed against so-called neoantigens: These are proteins that have undergone a genetic mutation in tumor cells and, therefore, differ from their counterparts in healthy cells. [More]
Study results pave way for new clinical trial for glioblastoma patients

Study results pave way for new clinical trial for glioblastoma patients

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research. [More]
New NIH grant to support development of rapid method for diagnosing mucormycosis

New NIH grant to support development of rapid method for diagnosing mucormycosis

Speed is essential in treating deadly mucormycosis fungal infections, but a quick diagnosis is difficult because no routine blood test exists. [More]
Scientists investigate how T cells in colorectal tumors actively fight cancer

Scientists investigate how T cells in colorectal tumors actively fight cancer

In recent years, a standard follow-up to colorectal cancer surgery has been to analyze the tumor tissue for the presence of immune cells. Finding high quantities of cytotoxic T cells, or "killer cells", means that there is a good chance that the disease will take a favorable course and that the risk of metastasis is comparatively low. [More]
BioMed Realty Trust expands footprint in Seattle's core innovation district of South Lake Union

BioMed Realty Trust expands footprint in Seattle's core innovation district of South Lake Union

BioMed Realty Trust, Inc. today announced that it is under contract to acquire the 307 Westlake Avenue North building in the heart of the burgeoning South Lake Union life science market of Seattle, Washington for approximately $90 million. [More]
MD Anderson and AstraZeneca to conduct multiple studies in ovarian, gynecologic cancers

MD Anderson and AstraZeneca to conduct multiple studies in ovarian, gynecologic cancers

The University of Texas MD Anderson Cancer Center and AstraZeneca today announced a multiyear strategic research collaboration to conduct multiple, parallel clinical and clinically related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes. [More]
TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today the receipt of the latest milestone payment of EUR 1 million from the Ovasave collaboration option, development and license agreement from Trizell (Trizell Holding SA). [More]

Bpifrance awards TxCell EUR 1.7 million grant for clinical development of Ovasave

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces the receipt of EUR 1.7 million from Bpifrance. [More]
TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present at the Cell & Gene Therapy Forum 2015, January 26 - 28, 2015 at Grand Hayatt in Washington DC, United States. [More]
Professor Jonathan Sprent named recipient of AAI Lifetime Achievement Award

Professor Jonathan Sprent named recipient of AAI Lifetime Achievement Award

The American Association of Immunologists has selected Professor Jonathan Sprent FAA FRS, from Sydney's Garvan Institute of Medical Research, to be the 2015 recipient of the AAI Lifetime Achievement Award. [More]
Tübingen researchers develop new way of labeling T-cells

Tübingen researchers develop new way of labeling T-cells

To better understand what happens during immune reactions in the body, researchers at Tübingen University have developed a new way of labeling T-cells, allowing them to track the T-cell movement in mice using non-invasive positron emission technology (PET). [More]
Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Intrexon Corporation, a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. [More]
TxCell announces further enhancement to development of Ovasave for IBD treatment

TxCell announces further enhancement to development of Ovasave for IBD treatment

Paulsen Foundation to provide specialist management and scientific and development expertise that is dedicated to advanced therapies, i.e. cellular and gene therapies. This new class of highly promising biological therapies includes TxCell’s Ovasave. [More]
Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014. [More]
Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

A study led by St. Jude Children's Research Hospital scientists has identified the population of white blood cells that tumors use to enhance growth and suppress the disease-fighting immune system. [More]
Inovio begins hTERT DNA immunotherapy trial in adults with breast, lung and pancreatic cancer

Inovio begins hTERT DNA immunotherapy trial in adults with breast, lung and pancreatic cancer

Inovio Pharmaceuticals, Inc. announced it has initiated a phase I trial of its hTERT DNA immunotherapy (INO-1400) alone or in combination with Inovio's IL-12 immune activator (INO-9012) in adults with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other cancer treatments. [More]
EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis. [More]
Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma. [More]